Jianchang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianchang Xu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Rutong Yu
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China
1 shared publication - Yanhong Ren
Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People’s Republic of China
1 shared publication - Zhengkui Zhang
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 6147483
ITGA1 Promotes Glioma Cell Proliferation and Affects Immune Cell Infiltration in Low‐Grade Glioma
Background: Low‐grade glioma (LGG) is a commonly occurring type of central nervous system cancer. Integrin α1 (ITGA1), a family member of integrins, is implied in the malignant development of cancers, but the fundamental role of ITGA1 has not been illustrated yet in glioma. This study aimed to evaluate the prognostic value of ITGA1.Methods: Correlations between ITGA1 and relevant clinical features were analyzed in the LGG datasets based on Chinese Glioma Genome Atlas (CGGA) and Tumor Genome Atlas (TCGA). Glioma clinical samples and glioma cell lines were identified at the level of mRNA and protein level by Western blot. Cox regression were developed to assess the involvement of ITGA1 expression in predicting survival in LGG patients. Application of GSEA enrichment analysis to reveal ITGA1‐mediated biological functions in LGG. Using TIMER 2.0 to analyze correlations between immune cell infiltration. In addition, ITGA1 high expression was analyzed for correlation with immune checkpoint‐related genes and cumulative survival time.Results: ITGA1 was significantly more expressed in LGG than in normal samples. Cox regression indicated that ITGA1 was a risk factor independently for prognosis in LGG patients. GSEA enrichment analysis indicated that ITGA1 was engaged in several immunomodulatory processes. ITGA1 expression was shown to be highly correlated with the immune score, stromal score, and estimate score in LGG. ITGA1 was significantly related to the immune checkpoint‐associated gene expression. In vivo experiments showed that overexpression of ITGA1 promoted glioma cell invasion.Conclusion: High ITGA1 expression is correlated with immune infiltration of the low‐grade tumor, leading to poor prognoses in LGG patients.
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 6147483
Open AccessITGA1 Promotes Glioma Cell Proliferation and Affects Immune Cell Infiltration in Low‐Grade Glioma
Background: Low‐grade glioma (LGG) is a commonly occurring type of central nervous system cancer. Integrin α1 (ITGA1), a family member of integrins, is implied in the malignant development of cancers, but the fundamental role of ITGA1 has not been illustrated yet in glioma. This study aimed to evaluate the prognostic value of ITGA1.Methods: Correlations between ITGA1 and relevant clinical features were analyzed in the LGG datasets based on Chinese Glioma Genome Atlas (CGGA) and Tumor Genome Atlas (TCGA). Glioma clinical samples and glioma cell lines were identified at the level of mRNA and protein level by Western blot. Cox regression were developed to assess the involvement of ITGA1 expression in predicting survival in LGG patients. Application of GSEA enrichment analysis to reveal ITGA1‐mediated biological functions in LGG. Using TIMER 2.0 to analyze correlations between immune cell infiltration. In addition, ITGA1 high expression was analyzed for correlation with immune checkpoint‐related genes and cumulative survival time.Results: ITGA1 was significantly more expressed in LGG than in normal samples. Cox regression indicated that ITGA1 was a risk factor independently for prognosis in LGG patients. GSEA enrichment analysis indicated that ITGA1 was engaged in several immunomodulatory processes. ITGA1 expression was shown to be highly correlated with the immune score, stromal score, and estimate score in LGG. ITGA1 was significantly related to the immune checkpoint‐associated gene expression. In vivo experiments showed that overexpression of ITGA1 promoted glioma cell invasion.Conclusion: High ITGA1 expression is correlated with immune infiltration of the low‐grade tumor, leading to poor prognoses in LGG patients.